Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.35 USD

35.35
4,497,383

-0.33 (-0.93%)

Updated Jul 19, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Cardiovascular Systems (CSII) Expands Lithotripsy Technology

by Zacks Equity Research

Cardiovascular Systems (CSII) has developed intravascular lithotripsy systems to treat calcific coronary and peripheral artery diseases.

New Strong Buy Stocks for January 17th

by Zacks Equity Research

AXS, BAX, F, UNFI, and BRDG have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2022.

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Debanjana Dey headshot

4 Stocks to Watch Out For as MedTech Rides on Buyout Frenzy

by Debanjana Dey

Here are some MedTech stocks - Quidel (QDEL), Thermo Fisher (TMO), Baxter (BAX) and BD (BDX) - that have been quite active in the acquisition front and therefore worth investor attention.

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp

Riya Anand headshot

4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic

by Riya Anand

Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.

Baxter's (BAX) $100M Investment to Strengthen Global Presence

by Zacks Equity Research

Baxter's (BAX) strategic investment to help expand the manufacturing footprint of BPS and ensure improvement in products.

Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) third-quarter results reflect robust performance across all its business units.

Baxter International (BAX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 8.51% and 0.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the third quarter despite the ongoing pandemic-led business challenges.

Baxter (BAX) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.

Baxter International (BAX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance at the Instruments & Accessories segment.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings

Debanjana Dey headshot

MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on

by Debanjana Dey

MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.

Baxter's (BAX) Premix Norepinephrine Now Available in U.S.

by Zacks Equity Research

Baxter's (BAX) norepinephrine can improve speed, efficiency and safety of treatment during critical care situations in hospital settings, and minimize compounding errors or touch contamination risks.

    Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How

    by Zacks Equity Research

    Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.

    Hill-Rom (HRC) Agrees to Get Acquired by Baxter, Shares Jump

    by Zacks Equity Research

    The transaction is expected to close by early 2022 subject to the approval of Hill-Rom (HRC) shareholders and the fulfillment of customary closing conditions.

    Baxter International (BAX) Q2 Earnings Surpass Estimates

    by Zacks Equity Research

    Baxter (BAX) delivered earnings and revenue surprises of 8.11% and -0.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Baxter (BAX) Q2 Earnings Surpass Estimates, Revenues Miss

    by Zacks Equity Research

    Baxter's (BAX) second-quarter results reflect robust performance across all its business units.

    Why the Earnings Surprise Streak Could Continue for Baxter (BAX)

    by Zacks Equity Research

    Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    DaVita (DVA) to Report Q2 Earnings: What's in the Offing?

    by Zacks Equity Research

    Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the second quarter despite ongoing pandemic-led higher PPE costs.

    Baxter (BAX) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    Baxter's (BAX) second-quarter results are likely to reflect growth in its Acute Therapies business.